Related Experiment Videos
Lymphocyte transformation in patients with cobalt dermatitis
The British Journal of Dermatology
|August 1, 1978
Summary
Cobalt chloride can help diagnose cobalt-induced contact dermatitis. A lymphocyte transformation test using cobalt chloride effectively identified patients with strongly positive patch tests, indicating allergic contact dermatitis.
Area of Science:
- Immunology
- Dermatology
- Allergy
Background:
- Cobalt allergy is a common cause of allergic contact dermatitis.
- Diagnosing cobalt allergy often relies on patch testing, but further in vitro confirmation can be beneficial.
Purpose of the Study:
- To evaluate the utility of a lymphocyte transformation test (LTT) using cobalt chloride for diagnosing cobalt-induced contact dermatitis.
- To determine if LTT can differentiate between patients with strongly and weakly positive cobalt patch tests and healthy controls.
Main Methods:
- A lymphocyte transformation test was conducted on 14 patients with cobalt-positive patch tests and dermatitis, and 9 controls.
- Cobalt chloride at a 1:5000 dilution in RPMI-1640 medium was used as the stimulant.
- Responses were compared to mitogens (phytohaemagglutinin, pokeweed mitogen, concanavalin A) and recall antigens (purified protein derivative, Candida albicans).
Main Results:
- Patients with strongly positive cobalt patch tests showed significantly higher lymphocyte transformation compared to controls.
- No significant difference in lymphocyte transformation was observed between patients with weakly positive patch tests and controls.
- The chosen cobalt chloride dilution effectively distinguished between strongly reactive patients and controls.
Conclusions:
- The lymphocyte transformation test with cobalt chloride is a valuable tool for diagnosing cobalt-induced contact dermatitis, particularly in patients with strong positive patch test reactions.
- LTT may offer a more objective measure of cellular hypersensitivity to cobalt than patch testing alone.
- Further investigation is warranted for patients with weakly positive patch tests.